Indivior Pharmaceuticals opened higher at $29.48, compared with its previous close of $29.45. In the last trading session, the stock traded between $28.79 and $30.18. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in Indivior Pharmaceuticals is now worth
$ 80.51
Resulting in a loss of
$ 19.49 (19.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-0.25 (-0.83%)
Day High
$30.18
Day Low
$28.79
Day Open
$29.48
Prev Close
$29.45
Volume
36,87,693
1W Return
3.38%
1M Return
-19.49%
3M Return
-19.49%
6M Return
-19.49%
1Y Return
-19.49%
Fundamentals
Market Cap ($ Mn)
6,067
PE Ratio
-
PB Ratio
2.47
PEG Ratio
-
ROE
-3.68%
ROCE
-5.72%
EPS (TTM)
$0.36
Investment Returns
1 Week
3.38%
1 Month
-19.49%
3 Months
-19.49%
6 Months
-19.49%
9 Months
-19.49%
Financials
Quarterly
All values in $ Mn
165.5
Jun 25
192.1
Sep 25
211.6
Dec 25
207.7
Mar 26
219.1
Jun 26
226.8
Sep 26
Updates
5Aug
Barclays Maintains Overweight on Indivior, Lowers Price Target to $43
Barclays keeps Indivior Pharmaceuticals at Overweight but cuts the price target to $43 from $46. Analyst Glen Santangelo cites revised valuation metrics while maintaining confidence in the company's long-term prospects.
Halper Sadeh LLC investigates the Indivior-Supernus merger, alleging fiduciary breaches and unfair pricing for INDV shareholders. The probe centers on whether the 56.5% post-merger ownership stake reflects true value. Shareholders are urged to contact the firm regarding potential claims for increased consideration.
3mo ago
3Aug
Indivior Pharmaceuticals Latest Results: Sales guidance raised to $1.365B
Indivior Pharmaceuticals raises FY2026 sales guidance to $1.295B-$1.365B, surpassing the $1.245B estimate. The update reflects improved operational outlook and exceeds the previous range of $1.215B-$1.285B.
3mo ago
18Jun
Barclays initiates coverage on Indivior with Overweight rating
Barclays analyst Glen Santangelo has initiated coverage on Indivior Pharmaceuticals with an Overweight rating and a price target of $46, indicating a positive outlook for the NASDAQ-listed stock.
